Higher locoregional recurrence rate for triple-negative XXXX following neoadjuvant chemotherapy, surgery and radiotherapy.

@entity172 @entity1 @entity0 @entity1420 @entity5948 @entity3907 @entity3918 @entity1722 @entity7443
BACKGROUND: @entity0 subtype, determined by expression of @entity172 / @entity1420 receptor (ER/PR) and @entity1 @entity1722 , is predictive for prognosis. The importance of subtype to locoregional recurrence (LRR) following neoadjuvant chemotherapy (NAC) is unknown, particularly after adjuvant radiotherapy (RT). METHODS: We retrospectively identified 160- @entity0 @entity1 registered at Columbia University Medical Center from 1999 to 2012 treated with NAC, surgery and adjuvant RT. RESULTS: @entity1 were grouped by receptor status: hormone receptor positive (HR+) [(ER or PR+)/ @entity1722 -; n  =  75], @entity1722 + (n  =  46), or triple-negative (TNBC) [ER (-) PR (-) @entity1722 (-); n  =  36]. The median follow-up was 28  months. 92.0% received an @entity5948 - @entity3907 based NAC and 80.4% of @entity1722 + @entity1 received trastuzumab. All underwent surgical resection followed by RT. 15.6% had a pathologic complete response (pCR): 26% of @entity1722 +, 5% of HR+, and 25% of @entity7443 . The actuarial rate of @entity3918 was 13.8% for the entire cohort, with equivalent rates by subtypes in non-pCR @entity1 . The overall rate of LRR was 8%. However, the LRR rate was significantly higher for TNBC @entity1 (22.2%) than @entity1722 + (5.6%) (p  =  0.025) or HR+ (3.0%) (p  =  0.037) in non-pCR group. In the pCR group, two @entity1 had recurrence; one LRR and one a @entity3918 , both had TNBC. All LRR occurred in or near the radiation field. CONCLUSIONS: TNBC @entity1 with  <  pCR to NAC have a significantly higher LRR rate as compared to other subtypes even with surgery and adjuvant RT. Our data support a need to further intensify local therapy in TNBC @entity1 .
